##plugins.themes.academic_pro.article.sidebar##

Download
pdf
Statistic
Read Counter : 0 Download : 0

##plugins.themes.academic_pro.article.main##

Abstract

The study's methodology involved enrolling 1,090 patients who had coronary angiography. Twenty-four indicators of inflammation were gathered before angiography. Distinct patterns of inflammatory biomarkers were identified by cluster analyses using unsupervised machine learning. The link between inflammatory biomarker clusters and individual biomarker associations with major adverse cardiovascular events (MACE; non-fatal myocardial infarction or stroke, and CV mortality) over a median follow-up of 3.67 years was evaluated using Cox proportional hazard regression.

Keywords

hazard events cardiovascular

##plugins.themes.academic_pro.article.details##

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

How to Cite
Shodiyev Mirshodbek Marufovich. (2024). Inflammatory Biomarkers’ Function in Cardiovascular Event Prediction. Journal of Pedagogical Inventions and Practices, 38, 5–13. Retrieved from https://zienjournals.com/index.php/jpip/article/view/5805

References

  1. Libby P. Atherosclerosis and inflammation. 2012;32:2045–51; Arterioscler Thromb Vasc Biol. 2.
  2. Tedgui A, Mallat Z, Taleb S, and Ait-Oufella H. Recent developments on the part cytokines play in
  3. atherosclerosis. 2011;31:969–79; Arterioscler Thromb Vasc Biol. October 2022, American Heart
  4. Journal
  5. Kalkman DN, Guedeney P, Claessen BE, et al. residual inflammatory risk in individuals
  6. undergoing percutaneous coronary intervention who have low LDL cholesterol. 73:2401–9, J Am
  7. Coll Cardiol, 2019.
  8. Hansson GK, Libby P. The week's JACC review subject ranges from systemic inflammation to
  9. localized lipid storage. 74:1594–607 in J Am Coll Cardiol, 2019.
  10. Godoy LC, Bhatt DL, Lawler PR, et al. Clinical translation's next stages in addressing
  11. cardiovascular inflammation. Eur Heart J 42:113–31, 2021.
  12. Lyass A, Liu Y, Gaggin HK, et al. Myocardial infarction incident type 2 in a group of patients
  13. receiving peripheral arterial or coronary angiography. Circulation 135:116–27, 2017.
  14. Consoli A, Bain SC, Marso SP, et al. Cardiovascular outcomes and semaglutide in individuals with
  15. type 2 diabetes. In 2016, N Engl J Med 375:1834–44.
  16. Cavender MA, Abadie BQ, and Cannon CP. new oral anticoagulants after coronary artery bypass
  17. surgery. Circ 2020; 13. Cardiovasc Interv 9. Stock JK. Future learning from studies on residual
  18. inflammatory risk. In 2020, Atherosclerosis 311:103–4.
  19. Libby P. The idea that inflammation causes atherosclerosis is no longer valid. 2021 Clin Chem
  20. :131–42.
  21. Everett BM, Thuren T, Ridker PM, et al. Canakinumab-based anti-inflammatory treatment for
  22. atherosclerotic disease. N Engl J Med 377:1119–31, 2017.
  23. IL-6 inhibition with ziltivekimab in patients at high atherosclerosis risk (RESCUE): a doubleblind, randomized, placebo-controlled, phase 2 study Ridker PM, Devalaraja M, Baeres FMM, et al.
  24. Lancet 397:2060-9.
  25. Deftereos SG, Shah B, Beerkens FJ, et al. Comprehensive overview of colchicine's role in
  26. cardiovascular disease. Circulation 145:61–78, 2022.
  27. Barraclough J, Robertson S, Martinez GJ, et al. Acute coronary syndrome patients' local cardiac
  28. production of inflammatory cytokines is abruptly suppressed by colchicine. 15. Ridker PM, Everett
  29. BM, Pradhan A, et al. J Am Heart Assoc 2015;4. Methotrexate at low doses to prevent atherosclerotic
  30. events. 2019; N Engl J Med;380:752–62.
  31. Ridker PM, Everett BM, MacFadyen JG, et al. A secondary analysis from the CANTOS
  32. randomised controlled trial examined the relationship between the decrease in C-reactive protein
  33. and the decrease in cardiovascular events after canakinumab medication. 2018;391:319–28;Lancet.
  34. Qiao JH, Mishra NK, Tripathi J, et al. Studies on osteopetrotic mice reveal the role of macrophage
  35. colony-stimulating factor in atherosclerosis. In 1997, Am J Pathol, 150:1687–99.
  36. Zolindaki MG, Pentzeridis PC, Rallidis LS, et al. In severe unstable angina, elevated levels of
  37. macrophage colony stimulating factor after the acute phase are highly indicative of long-term
  38. results. Heart, 2004; 90:25–9.
  39. Vasudevan SS, Kereiakes DJ, Seshiah PN, et al. The function of cell contact and macrophage
  40. colony-stimulating factor in the smooth muscle cell death caused by activated monocytes.
  41. Circulation 105:174–80, 2002.
  42. Philippova M, Oskolkova O, Bochkov VN, et al. Through autocrine pathways, oxidized
  43. phospholipids promote angiogenesis, suggesting a new function for lipid oxidation in the
  44. development of atherosclerotic lesions. 2006;99:900–8; Circ Res.